Trastuzumab in Treating Patients With Prostate Cancer

Summary

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of trastuzumab in treating patients who have prostate cancer that has not responded to hormone therapy.

Timeline

Start

1998-10

Primary completion

2002-09

Completion

2002-09

Drugs

Indications